(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 27.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Immatics Nv's revenue in 2026 is $43,878,823.On average, 13 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,587,745,514, with the lowest IMTX revenue forecast at $2,678,793,956, and the highest IMTX revenue forecast at $8,423,850,278. On average, 13 Wall Street analysts forecast IMTX's revenue for 2027 to be $6,441,679,424, with the lowest IMTX revenue forecast at $1,111,699,492, and the highest IMTX revenue forecast at $11,222,233,250.
In 2028, IMTX is forecast to generate $14,100,570,020 in revenue, with the lowest revenue forecast at $5,598,679,367 and the highest revenue forecast at $21,296,411,947.